TCPG
ABBV icon

Trivant Custom Portfolio Group’s AbbVie ABBV Stock Holding History

Trivant Custom Portfolio Group’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-100
Closed -$21K – 102
2025
Q1 		$21K Hold
100
– – 0.01% 127
2024
Q4 		$17.8K Hold
100
– – 0.01% 121
2024
Q3 		$19.7K Hold
100
– – 0.01% 116
2024
Q2 		$17.2K Hold
100
– – 0.01% 136
2024
Q1 		$18.2K Hold
100
– – 0.01% 138
2023
Q4 		$15.5K Hold
100
– – 0.01% 154
2023
Q3 		$14.9K Hold
100
– – 0.01% 144
2023
Q2 		$13.5K Hold
100
– – 0.01% 163
2023
Q1 		$15.9K Buy
+100
New +$15.3K 0.01% 165

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Trivant Custom Portfolio Group's ABBV Position: Q2 2025 in Review

Trivant Custom Portfolio Group sold out of AbbVie (ABBV) in Q2 2025, closing a stake of 100 shares — an estimated $21K sold.

Trivant Custom Portfolio Group first reported a position in ABBV in Q1 2023 and held it in 9 quarters. The position peaked at $21K in Q1 2025. 3,780 funds tracked by Wall St. Rank hold ABBV as of Q2 2025.

  • Trivant Custom Portfolio Group reported no remaining AbbVie position as of Q2 2025 after selling out during the quarter.
  • Trivant Custom Portfolio Group sold 100 AbbVie shares in Q2 2025, an estimated $21K.
  • Trivant Custom Portfolio Group first reported a position in AbbVie in Q1 2023 and held it in 9 quarters.
  • Trivant Custom Portfolio Group's AbbVie position peaked at $21K in Q1 2025.
  • 3,780 funds tracked by Wall St. Rank held AbbVie as of Q2 2025.

Based on Trivant Custom Portfolio Group's 13F filing for Q2 2025, filed 12 Aug 2025.